3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Melanoma
5
Lung Neoplasms
3
Urinary Bladder Neoplasms
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Esophageal Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Neoplasms, Squamous Cell
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Chondrosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Adenocarcinoma
1
Interventions
pembrolizumab
30
Nivolumab
12
Carboplatin
6
atezolizumab
5
Trastuzumab
5
aldesleukin
4
Specimen Handling
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Docetaxel
4
Cyclophosphamide
4
Cisplatin
4
Bevacizumab
4
spartalizumab
3
fludarabine
3
durvalumab
3
Polymerase Chain Reaction
3
Irinotecan
3
Interleukin-2
3
Gene Expression Profiling
3
Blood Specimen Collection
3
Biopsy
3
zimberelimab
2
tisotumab vedotin
2
tislelizumab
2
sargramostim
2
osimertinib
2
enzalutamide
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
poly ICLC
×
Thoracic
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled